Arcellx Yönetim

Yönetim kriter kontrolleri 2/4

Arcellx CEO'su Rami Elghandour, Jan2021 tarihinde atandı, in görev süresi 3.83 yıldır. in toplam yıllık tazminatı $ 24.96M olup, şirket hissesi ve opsiyonları dahil olmak üzere 2.4% maaş ve 97.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.13% ine doğrudan sahiptir ve bu hisseler $ 6.26M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.5 yıl ve 4.3 yıldır.

Anahtar bilgiler

Rami Elghandour

İcra Kurulu Başkanı

US$25.0m

Toplam tazminat

CEO maaş yüzdesi	2.4%
CEO görev süresi	3.8yrs
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	3.5yrs
Yönetim Kurulu ortalama görev süresi	4.3yrs

Son yönetim güncellemeleri

Recent updates

A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)

Oct 28

Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma

Sep 10

There's Reason For Concern Over Arcellx, Inc.'s (NASDAQ:ACLX) Massive 28% Price Jump

Sep 05

We're Interested To See How Arcellx (NASDAQ:ACLX) Uses Its Cash Hoard To Grow

Aug 10

A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)

Jul 12

News Flash: Analysts Just Made A Sizeable Upgrade To Their Arcellx, Inc. (NASDAQ:ACLX) Forecasts

Jun 01

Rainbows and Unicorns: Arcellx, Inc. (NASDAQ:ACLX) Analysts Just Became A Lot More Optimistic

May 14

Is Arcellx (NASDAQ:ACLX) A Risky Investment?

May 12

Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 01

Arcellx: Navigating The CAR T-Cell Revolution

Jan 30

Need To Know: Analysts Are Much More Bullish On Arcellx, Inc. (NASDAQ:ACLX) Revenues

Nov 18

Earnings Miss: Arcellx, Inc. Missed EPS And Analysts Are Revising Their Forecasts

May 10

CEO Tazminat Analizi

Rami Elghandour'un ücretlendirmesi Arcellx'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$40m
Jun 30 2024	n/a	n/a	-US$54m
Mar 31 2024	n/a	n/a	-US$51m
Dec 31 2023	US$25m	US$601k	-US$71m
Sep 30 2023	n/a	n/a	-US$130m
Jun 30 2023	n/a	n/a	-US$183m
Mar 31 2023	n/a	n/a	-US$190m
Dec 31 2022	US$14m	US$565k	-US$189m
Sep 30 2022	n/a	n/a	-US$170m
Jun 30 2022	n/a	n/a	-US$95m
Mar 31 2022	n/a	n/a	-US$80m
Dec 31 2021	US$23m	US$470k	-US$65m

Tazminat ve Piyasa: Rami 'nin toplam tazminatı ($USD 24.96M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 7.74M ).

Tazminat ve Kazançlar: Rami şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Rami Elghandour (45 yo)

3.8yrs

Görev süresi

US$24,964,306

Tazminat

Mr. Rami Elghandour serves as President, Chief Executive Officer and Chairman of the Board of Directors at Arcellx, Inc. since January 2021. Mr. Elghandour joined the Arcellx, Inc. on January 22, 2021. Pre...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Rami Elghandour	Chairman of the Board	3.8yrs	US$24.96m	0.13% $ 6.3m
Michelle Gilson	Chief Financial Officer	2.5yrs	US$3.55m	0.0056% $ 271.4k
Christopher Heery	Chief Medical Officer	3.6yrs	US$3.86m	0.017% $ 839.2k
Narinderjeet Singh	Chief Technical Officer	3.1yrs	Veri yok	Veri yok
David Tice	Chief Scientific Officer	3.3yrs	Veri yok	Veri yok
Myesha Lacy	Chief Investor & Communications Officer	3.8yrs	Veri yok	Veri yok
Maryam Abdul-Kareem	General Counsel & Chief Legal Officer	2.4yrs	Veri yok	Veri yok
Kate Aiken	Chief People Officer	3.8yrs	Veri yok	Veri yok
Neeraj Teotia	Chief Commercial Officer	3.6yrs	US$2.00m	Veri yok
Aileen Fernandes	Chief Business Officer	2.4yrs	Veri yok	Veri yok

3.5yrs

Ortalama Görev Süresi

47yo

Ortalama Yaş

Deneyimli Yönetim: ACLX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Rami Elghandour	Chairman of the Board	3.8yrs	US$24.96m	0.13% $ 6.3m
David Lubner	Independent Director	4.3yrs	US$359.67k	0.040% $ 2.0m
Ali Behbahani	Independent Director	9.8yrs	US$355.17k	0.00078% $ 38.1k
Jill Carroll	Independent Director	7.2yrs	US$353.67k	Veri yok
Derek Yoon	Independent Director	4.6yrs	US$347.17k	Veri yok
Olivia Ware	Independent Director	2.5yrs	US$343.67k	Veri yok
Kavita Patel	Independent Director	2.9yrs	US$344.67k	Veri yok

4.3yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ACLX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).

Arcellx Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Chief Financial Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Chief Medical Officer exercised options and sold US$320k worth of stock

Chief Medical Officer exercised options and sold US$990k worth of stock

Recent updates

Consensus EPS estimates fall by 11%

Chief Financial Officer notifies of intention to sell stock

Price target increased by 9.7% to US$105

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)

Independent Director notifies of intention to sell stock

Price target increased by 7.1% to US$89.67

Now 20% overvalued after recent price rise

Chief Financial Officer notifies of intention to sell stock

Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma

There's Reason For Concern Over Arcellx, Inc.'s (NASDAQ:ACLX) Massive 28% Price Jump

Chief Medical Officer notifies of intention to sell stock

Chief Medical Officer exercised options and sold US$320k worth of stock

Consensus revenue estimates increase by 21%

We're Interested To See How Arcellx (NASDAQ:ACLX) Uses Its Cash Hoard To Grow

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Now 21% undervalued after recent price drop

Chief Medical Officer exercised options and sold US$990k worth of stock

Now 21% overvalued after recent price rise

A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)

Chief Financial Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Now 21% undervalued after recent price drop

New major risk - Revenue and earnings growth

News Flash: Analysts Just Made A Sizeable Upgrade To Their Arcellx, Inc. (NASDAQ:ACLX) Forecasts

Consensus revenue estimates increase by 14%

Chief Financial Officer notifies of intention to sell stock

Consensus revenue estimates increase by 11%

Rainbows and Unicorns: Arcellx, Inc. (NASDAQ:ACLX) Analysts Just Became A Lot More Optimistic

Is Arcellx (NASDAQ:ACLX) A Risky Investment?

New major risk - Revenue and earnings growth

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Chief Medical Officer exercised options and sold US$818k worth of stock

Arcellx, Inc., Annual General Meeting, May 24, 2024

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 10%

Price target increased by 13% to US$75.92

Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 10.0% to US$72.27

Chairman of the Board recently sold US$2.4m worth of stock

New major risk - Revenue and earnings growth

Chairman of the Board notifies of intention to sell stock

Arcellx: Navigating The CAR T-Cell Revolution

Chairman of the Board recently sold US$1.6m worth of stock

Chairman of the Board notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Price target increased by 8.5% to US$65.18

Arcellx, Inc. Announces Continued Robust Long-Term Responses from its Cart-Ddbcma Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma At Ash

Need To Know: Analysts Are Much More Bullish On Arcellx, Inc. (NASDAQ:ACLX) Revenues

Arcellx, Inc. announced that it expects to receive $199.999991 million in funding from Gilead Sciences, Inc.

Price target increased by 9.5% to US$56.55

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 11%

Arcellx, Inc. Announces Oral Presentation for CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma At the 65th ASH Annual Meeting and Exposition

Consensus revenue estimates fall by 47%

Arcellx, Inc. Announces Partial Clinical Hold Lifted on Immagine-1 Phase 2 Clinical Program

Arcellx, Inc. Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program

Chairman of the Board recently sold US$115k worth of stock

Consensus EPS estimates fall by 365%

Price target increased by 12% to US$47.56

Earnings Miss: Arcellx, Inc. Missed EPS And Analysts Are Revising Their Forecasts

Price target increased by 9.2% to US$43.56

Chief Medical Officer notifies of intention to sell stock

Price target increased by 7.9% to US$42.33

Chief Medical Officer exercised options and sold US$404k worth of stock

Chief Medical Officer notifies of intention to sell stock

Arcellx, Inc. announced that it has received $100.000004 million in funding from Gilead Sciences, Inc.

Insider recently sold US$51k worth of stock